New treatment targeting cancer cells and their supportive environment in Non-Hodgkin Lymphoma.
Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).
['FUNDING_SBIR_2'] · BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC. · NIH-10911718
This study is testing a new treatment called BITR2101 that targets a specific part of cancer cells to help stop the growth of Non-Hodgkin Lymphoma, especially for those with Cutaneous T Cell Lymphoma, and it may be used on its own or with other therapies to improve patient outcomes.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (WINCHESTER, UNITED STATES) |
| Trial ID | NIH-10911718 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel antibody, BITR2101, that targets TNFR2, a receptor found in cancer cells and their surrounding supportive cells. By inhibiting TNFR2 signaling, the treatment aims to disrupt the cancer's ability to grow and resist therapy. Patients will be evaluated for their response to this innovative therapy, which may be used alone or in combination with other treatments. The study seeks to improve outcomes for patients with Non-Hodgkin Lymphoma, particularly those with Cutaneous T Cell Lymphoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Non-Hodgkin Lymphoma, especially those with Cutaneous T Cell Lymphoma.
Not a fit: Patients with other types of cancer or those who do not express TNFR2 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Non-Hodgkin Lymphoma, improving survival rates and quality of life for patients.
How similar studies have performed: Other research has shown promise in targeting similar pathways in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
WINCHESTER, UNITED STATES
- BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC. — WINCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BROOKS, DAVID G — BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC.
- Study coordinator: BROOKS, DAVID G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.